Financials · OBIO

Orchestra BioMed Holdings Inc. (OBIO) financials

For the twelve months ended Sep 30, 2026, Orchestra BioMed Holdings Inc. reported $31.21M of revenue and -$56.95M of net income.

Revenue, TTM
$31.21M
Revenue growth, YoY
+1007.4%
Net income, TTM
-$56.95M
Net margin
-182.5%
Free cash flow, TTM
-$64.18M
Cash
$27.76M
Total debt
$21.15M
P/S
17.96
Market cap
$560.4M
Annual revenue$33.48M
FY2022FY2025
Annual net income-$52.70M
FY2021FY2025
Annual free cash flow-$49.45M
FY2022FY2025

OBIO revenue and earnings growth

OBIO revenueQ3 2026$91.0K

Quarter YoY
-89.4%
QoQ
+3.4%
FY YoY
13x

OBIO revenue was $91.0K in fiscal Q3 2026 (ended Sep 30, 2026), down 89.4% from a year earlier and up 3.4% from the prior quarter. For the full fiscal 2025 it was $33.48M, up about 13-fold from fiscal 2024. It rose in 1 of the last 3 fiscal years.

OBIO net incomeQ3 2026-$18.75M

OBIO net income was -$18.75M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$20.83M a year earlier. For the full fiscal 2025 it was -$52.70M, compared with -$61.02M in fiscal 2024.

OBIO EPSQ3 2026-$0.30

OBIO diluted EPS was -$0.30 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.40 a year earlier. For the full fiscal 2025 it was -$1.11, compared with -$1.66 in fiscal 2024.

OBIO free cash flowQ3 2026-$19.94M

OBIO free cash flow was -$19.94M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$14.86M a year earlier. For the full fiscal 2025 it was -$49.45M, compared with -$50.85M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Revenue$33.48M$2.64M$2.76M$3.53M-
Cost of revenue$190.0K$204.0K$186.0K$211.0K-
Gross profit$33.29M$2.43M$2.57M$3.32M-
Research and development$58.19M$42.80M$33.82M$21.95M-
Selling, general and admin$26.91M$23.93M$20.26M$14.03M$274.8K
Operating income-$51.81M-$64.30M-$51.51M-$32.66M-$394.8K
Income tax$0----
Net income-$52.70M-$61.02M-$49.12M-$33.61M-$378.8K
EPS, basic-$1.11-$1.66-$1.48-$2.24-$0.02
EPS, diluted-$1.11-$1.66-$1.48-$2.24-$0.02
Diluted shares47.7M36.8M33.2M15.0M20.4M

Balance sheet

Balance sheet
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Cash and equivalents$34.69M$22.26M$30.56M$19.78M$9.94M
Short-term investments$71.82M$44.55M$56.97M$63.91M-
Receivables$95.0K$92.0K$99.0K$96.0K-
Inventory$310.0K$173.0K$146.0K$276.0K-
Current assets$107.91M$69.17M$89.11M$84.69M$1.80M
Total assets$114.86M$76.17M$95.21M$95.57M$161.82M
Current liabilities$16.74M$16.21M$11.21M$18.57M$165.5K
Total debt$15.00M$15.00M---
Total liabilities$51.48M$43.22M$27.17M$43.04M$5.77M
Shareholders' equity$53.57M$32.96M$68.04M$52.53M-$19.78M

Cash flow

Cash flow
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Operating cash flow-$48.96M-$50.56M-$46.13M-$29.29M-$272.4K
Capital expenditures$489.0K$289.0K$78.0K$591.0K-
Free cash flow-$49.45M-$50.85M-$46.20M-$29.88M-
Investing cash flow-$26.94M$13.09M$10.69M-$64.12M-
Financing cash flow$88.33M$29.17M$46.22M$103.26M-
Stock-based compensation$11.98M$10.62M$7.63M$3.38M-
Depreciation and amortization$327.0K$308.0K$287.0K$222.0K-

Key ratios

Key ratios
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Revenue growth, YoY1169.2%-4.4%-21.9%--
Gross margin99.4%92.3%93.3%94.0%-
Operating margin-154.7%-2437.5%-1866.2%-924.3%-
Net margin-157.4%-2313.3%-1779.7%-951.3%-
Free cash flow margin-147.7%-1927.5%-1674.1%-845.7%-
Return on equity-98.4%-185.2%-72.2%-64.0%-
Return on assets-45.9%-80.1%-51.6%-35.2%-0.2%
Current ratio6.454.277.954.5610.88
Debt to equity0.280.46---

Source: XBRL data Orchestra BioMed Holdings Inc. files with the SEC, latest filing dated Nov 10, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

OBIO peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
OBIO$31.21M+1007.4%-$56.95M-182.5%$560.4M
MDT$37.54B+9.8%$5.24B14.0%$131.60B
BSX$21.07B+8.9%$3.50B16.6%$63.33B
ABT$48.23B+10.0%$4.70B9.7%$186.10B
IRTC$854.04M+21.6%-$38.59M-4.5%$3.05B

OBIO FAQ

8 questions
  • What is OBIO revenue?
    Orchestra BioMed Holdings Inc. (OBIO) reported $31.21M of revenue for the twelve months ended Sep 30, 2026. That is up 1007.4% from the year before. Revenue for fiscal 2025 was $33.48M.
  • Is OBIO profitable?
    No. Orchestra BioMed Holdings Inc. reported a net loss of $56.95M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does OBIO have?
    Orchestra BioMed Holdings Inc. reported $27.76M in cash and cash equivalents and $21.15M of debt on its most recent balance sheet in SEC filings.
  • How fast is OBIO revenue growing?
    Orchestra BioMed Holdings Inc.'s revenue changed 13x in fiscal 2025, to $33.48M.
  • What is OBIO gross margin?
    Orchestra BioMed Holdings Inc.'s gross profit was $31.07M on $31.21M of revenue for the twelve months ended Sep 30, 2026, a gross margin of 99.6%.
  • What is OBIO free cash flow?
    Orchestra BioMed Holdings Inc. generated -$64.18M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$63.31M less capital expenditures.
  • When did OBIO last report financial results?
    The latest statements here come from Orchestra BioMed Holdings Inc.'s 10-Q filed on Nov 10, 2026, covering the period ended Sep 30, 2026.
  • Where does this OBIO financial data come from?
    Quantisnow builds these statements from the structured XBRL data Orchestra BioMed Holdings Inc. files with the SEC. It is provided for information only and is not investment advice.